Meryeme Lahmami

Principal

HQ Location

Montréal, QC

Meryeme Lahmami is a Principal at Pender Ventures, bringing a founder’s perspective and more than a decade of experience in company building and venture investing. Before joining the firm, she invested in early-stage and growth companies at BDC Capital across enterprise software, biotech and digital health. She also co-founded a venture-backed health tech startup. Her experience combines a broad technology lens with deep roots in health tech and firsthand knowledge of the decisions founders face as they build and grow their businesses. Meryeme serves on the boards of Science & Humans, DistillerSR, DrugBank and InsideDesk.

Investments

Earlier in her career, Meryeme focused her investment work on digital health and diagnostics. She holds an MBA from Université Laval.

Featured Insights

  • Announcing our Investment in Science&Humans

    We are thrilled to announce our investment in Science&Humans, a company building an integrated platform for hormone health through at-home diagnostics, virtual clinical consults and vertically integrated pharmacy experience. The investment comes as part of a Series A financing that we led with participation from WELL health, Michele Romanow and a group of US-based family […]

  • Canadian Health Tech Funding and Trends Report – 2025 Year in Review

    Welcome to Pender Ventures’ 4th Annual Canadian Health Tech Funding & Trends Report. As long-term investors in software and healthcare, we see the market up close, through financings, exits, and the day-to-day realities of building companies. This report is our opportunity to step back from the noise and take a clear-eyed view of where capital […]

  • Canadian Health Tech Funding and Trends Report – 2024 Year in Review

    Welcome to our third annual report where we examine the Canadian health tech investment landscape across public and private markets and provide an overview of key current trends we are seeing.  2024 was another challenging year for Canadian health tech, with venture funding dropping 18% compared to 2023, ending at $700M across 287 deals. Early-stage […]